We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Co-Development Partnership for Anti-Cancer Programme

Co-Development Partnership for Anti-Cancer Programme

Co-Development Partnership for Anti-Cancer Programme

Co-Development Partnership for Anti-Cancer Programme

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Co-Development Partnership for Anti-Cancer Programme"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CellCentric and Cancer Research Technology Ltd (CRT) have announced that they have begun an anti-cancer co-development programme. 

The programme of two phases aims to initially validate CellCentric’s epigenetic-related lead cancer target, and subsequently develop monoclonal antibody therapeutic products.  

Both parties will share the costs and rewards of the collaboration which may be followed by the co-development of other targets identified by CellCentric.

CellCentric’s technology is based on its understanding of epigenetic mechanisms that control cell function and fate. 

Many cancers have abnormal epigenetic profiles and by targeting errant epigenetic mechanisms, cancer cells can be selected for destruction. 

CellCentric has identified several proteins that influence cell fate and are clear candidates for the development of cancer therapeutics. 

Commenting on the news, Dr Will West, CellCentric’s COO said, “Collaborating with CRT is a very important next step for CellCentric in working towards product development from its epigenetics research platform.”

“Working with a partner of the calibre of CRT demonstrates great confidence in the potential of CellCentric’s epigenetics discovery base.”

“It is encouraging to see that, in such a short time, we have progressed our epigenetics research to a stage where collaboration is possible.”